Qiagen (NYSE:QGEN) was upgraded by equities researchers at Exane BNP Paribas from a “neutral” rating to an “outperform” rating in a report released on Friday, The Fly reports.
A number of other brokerages have also commented on QGEN. Deutsche Bank lowered Ontex Group from a “buy” rating to a “hold” rating in a report on Wednesday, May 8th. Zacks Investment Research lowered Great Portland Estates from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. BNP Paribas raised Qiagen from a “neutral” rating to an “outperform” rating in a report on Friday. Goldman Sachs Group lowered JSR from a “neutral” rating to a “sell” rating in a report on Friday, June 21st. Finally, Barclays increased their target price on from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the stock an “equal weight” rating in a report on Friday, June 21st. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $42.00.
NYSE QGEN traded down $0.05 on Friday, reaching $39.74. The stock had a trading volume of 60,918 shares, compared to its average volume of 800,221. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.52 and a current ratio of 1.69. The stock’s fifty day moving average is $39.51. Qiagen has a 1-year low of $32.33 and a 1-year high of $41.55. The stock has a market capitalization of $9.02 billion, a P/E ratio of 29.62, a P/E/G ratio of 2.46 and a beta of 0.84.
Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The firm had revenue of $348.70 million for the quarter, compared to analyst estimates of $351.68 million. During the same period in the prior year, the firm posted $0.26 EPS. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. Analysts forecast that Qiagen will post 1.43 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC bought a new position in Qiagen in the fourth quarter valued at about $25,000. O Shaughnessy Asset Management LLC bought a new position in Qiagen in the first quarter valued at about $30,000. Captrust Financial Advisors raised its position in shares of Qiagen by 165.3% during the fourth quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock worth $35,000 after acquiring an additional 628 shares during the last quarter. Cornerstone Advisors Inc. bought a new stake in Qiagen in the first quarter worth approximately $44,000. Finally, Bremer Trust National Association bought a new stake in Qiagen in the fourth quarter worth approximately $45,000. 63.22% of the stock is currently owned by institutional investors and hedge funds.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Recommended Story: Diversification in Investing
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.